These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 9078536

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
    Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA.
    Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans.
    Vollmer K, Gardiwal H, Menge BA, Goetze O, Deacon CF, Schmidt WE, Holst JJ, Meier JJ.
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1379-85. PubMed ID: 19174495
    [Abstract] [Full Text] [Related]

  • 7. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans.
    Meier JJ, Holst JJ, Schmidt WE, Nauck MA.
    Am J Physiol Endocrinol Metab; 2007 Sep; 293(3):E849-56. PubMed ID: 17609256
    [Abstract] [Full Text] [Related]

  • 8. Augmentation of alimentary insulin secretion despite similar gastric inhibitory peptide (GIP) responses in juvenile obesity.
    Heptulla RA, Tamborlane WV, Cavaghan M, Bronson M, Limb C, Ma YZ, Sherwin RS, Caprio S.
    Pediatr Res; 2000 May; 47(5):628-33. PubMed ID: 10813588
    [Abstract] [Full Text] [Related]

  • 9. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
    Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O'Donovan D, Rayner CK, Horowitz M.
    Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226
    [Abstract] [Full Text] [Related]

  • 10. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM.
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
    [Abstract] [Full Text] [Related]

  • 11. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
    Pacini G, Thomaseth K, Ahrén B.
    Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
    [Abstract] [Full Text] [Related]

  • 12. What do we know about the secretion and degradation of incretin hormones?
    Deacon CF.
    Regul Pept; 2005 Jun 15; 128(2):117-24. PubMed ID: 15780431
    [Abstract] [Full Text] [Related]

  • 13. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
    Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK.
    Am J Physiol Endocrinol Metab; 2011 Jun 15; 300(6):E1038-46. PubMed ID: 21386059
    [Abstract] [Full Text] [Related]

  • 14. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ.
    Diabetes; 2008 Mar 15; 57(3):678-87. PubMed ID: 18057091
    [Abstract] [Full Text] [Related]

  • 15. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Diabetologia; 2002 Aug 15; 45(8):1111-9. PubMed ID: 12189441
    [Abstract] [Full Text] [Related]

  • 16. Incretin and islet hormonal responses to fat and protein ingestion in healthy men.
    Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahrén B.
    Am J Physiol Endocrinol Metab; 2008 Oct 15; 295(4):E779-84. PubMed ID: 18612044
    [Abstract] [Full Text] [Related]

  • 17. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O, Haugaard SB, Holst JJ, Deacon CF, Iversen J, Andersen UB, Nielsen JO, Madsbad S.
    HIV Med; 2005 Mar 15; 6(2):91-8. PubMed ID: 15807714
    [Abstract] [Full Text] [Related]

  • 18. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF, Nilas L, Madsbad S, Holst JJ.
    Metabolism; 2009 May 15; 58(5):586-93. PubMed ID: 19375579
    [Abstract] [Full Text] [Related]

  • 19. Glucose-induced incretin hormone release and insulin sensitivity are impaired in patients with idiopathic gastroparesis: results from a pilot descriptive study.
    Prévost G, Ducrotté P, Cailleux A, Khalfi K, Basuyau JP, Lefebvre H, Kuhn JM.
    Neurogastroenterol Motil; 2013 Aug 15; 25(8):694-9. PubMed ID: 23663508
    [Abstract] [Full Text] [Related]

  • 20. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A.
    Dan Med J; 2017 Apr 15; 64(4):. PubMed ID: 28385175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.